These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Narula PK; Rehan HS; Unni KE; Gupta N Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521 [TBL] [Abstract][Full Text] [Related]
44. Impaired verbal fluency under topiramate--evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy. Witt JA; Elger CE; Helmstaedter C Eur J Neurol; 2013 Jan; 20(1):130-7. PubMed ID: 22827489 [TBL] [Abstract][Full Text] [Related]
45. The effects of glycine on auditory mismatch negativity in schizophrenia. Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646 [TBL] [Abstract][Full Text] [Related]
46. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]
47. Use of topiramate in treatment-resistant bipolar spectrum disorders. Vieta E; Torrent C; Garcia-Ribas G; Gilabert A; Garcia-Parés G; Rodriguez A; Cadevall J; García-Castrillón J; Lusilla P; Arrufat F J Clin Psychopharmacol; 2002 Aug; 22(4):431-5. PubMed ID: 12172346 [TBL] [Abstract][Full Text] [Related]
48. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. McElroy SL; Shapira NA; Arnold LM; Keck PE; Rosenthal NR; Wu SC; Capece JA; Fazzio L; Hudson JI J Clin Psychiatry; 2004 Nov; 65(11):1463-9. PubMed ID: 15554757 [TBL] [Abstract][Full Text] [Related]
49. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. Follett PL; Deng W; Dai W; Talos DM; Massillon LJ; Rosenberg PA; Volpe JJ; Jensen FE J Neurosci; 2004 May; 24(18):4412-20. PubMed ID: 15128855 [TBL] [Abstract][Full Text] [Related]
50. Timing and clinical characteristics of topiramate-induced psychosis in a patient with epilepsy and tuberous sclerosis. Pasini A; Pitzianti M; Baratta A; Moavero R; Curatolo P Clin Neuropharmacol; 2014; 37(1):38-9. PubMed ID: 24434533 [TBL] [Abstract][Full Text] [Related]
51. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Houthoofd SA; Morrens M; Sabbe BG Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365 [TBL] [Abstract][Full Text] [Related]
52. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Lévy E; Agbokou C; Ferreri F; Chouinard G; Margolese HC Can J Clin Pharmacol; 2007; 14(2):e234-9. PubMed ID: 17565171 [TBL] [Abstract][Full Text] [Related]
53. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Coyle JT; Tsai G; Goff D Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455 [TBL] [Abstract][Full Text] [Related]
54. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. Lohr JB; Liu L; Caligiuri MP; Kash TP; May TA; Murphy JD; Ancoli-Israel S Schizophr Res; 2013 Oct; 150(1):289-96. PubMed ID: 23938173 [TBL] [Abstract][Full Text] [Related]
56. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M; Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569 [TBL] [Abstract][Full Text] [Related]
57. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. Hofer A; Fleischhacker WW; Hummer M J Clin Psychiatry; 2003 Oct; 64(10):1267-8. PubMed ID: 14658980 [No Abstract] [Full Text] [Related]
58. D-alanine added to antipsychotics for the treatment of schizophrenia. Tsai GE; Yang P; Chang YC; Chong MY Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544 [TBL] [Abstract][Full Text] [Related]
59. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774 [TBL] [Abstract][Full Text] [Related]
60. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Harvey PD; Napolitano JA; Mao L; Gharabawi G Int J Geriatr Psychiatry; 2003 Sep; 18(9):820-9. PubMed ID: 12949850 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]